Baystreet Staff - Wednesday, December 16, 2015 Acasti Pharma Inc. 10:02 AM EST - Acasti Pharma Inc. : Has received positive feedback from the U.S. Food and Drug Administration (FDA) on the proposed development pathway for CaPre®. Acasti Pharma Inc. shares V.APO are trading up $1.83 at $4.02.